|
1
|
Oda Y, Tateishi N, Matono H, et al:
Chemokine receptor CXCR4 expression is correlated with VEGF
expression and poor survival in soft-tissue sarcoma. Int J Cancer.
124:1852–1859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim RH, Li BD and Chu QD: The role of
chemokine receptor CXCR4 in the biologic behavior of human soft
tissue sarcoma. Sarcoma. 2011:5937082011.PubMed/NCBI
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mankin HJ, Hornicek FJ, Rosenberg AE,
Harmon DC and Gebhardt MC: Survival data for 648 patients with
osteosarcoma treated at one institution. Clin Orthop Relat Res.
429:286–291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bentzen SM: Prognostic factor studies in
oncology: osteosarcoma as a clinical example. Int J Radiat Oncol
Biol Phys. 49:513–518. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Namløs HM, Kresse SH, Müller CR, et al:
Global gene expression profiling of human osteosarcomas reveals
metastasis-associated chemokine pattern. Sarcoma.
2012:6390382012.PubMed/NCBI
|
|
7
|
Clark JC, Akiyama T, Dass CR and Choong
PF: New clinically relevant, orthotopic mouse models of human
chondrosarcoma with spontaneous metastasis. Cancer Cell Int.
10:202010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hemmati M, Abbaspour A, Alizadeh AM, et
al: Rat xenograft chondrosarcoma development by human tissue
fragment. Exp Oncol. 33:52–54. 2011.PubMed/NCBI
|
|
9
|
Li TM, Lin TY, Hsu SF, et al: The novel
benzimidazole derivative, MPTB, induces cell apoptosis in human
chondrosarcoma cells. Mol Carcinog. 50:791–803. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bergh P, Gunterberg B, Meis-Kindblom JM
and Kindblom LG: Prognostic factors and outcome of pelvic, sacral,
and spinal chondrosarcomas: a center-based study of 69 cases.
Cancer. 91:1201–1212. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fiorenza F, Abudu A, Grimer RJ, et al:
Risk factors for survival and local control in chondrosarcoma of
bone. J Bone Joint Surg Br. 84:93–99. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bruns J, Elbracht M and Niggemeyer O:
Chondrosarcoma of bone: an oncological and functional follow-up
study. Ann Oncol. 12:859–864. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qureshi A, Ahmad Z, Azam M and Idrees R:
Epidemiological data for common bone sarcomas. Asian Pac J Cancer
Prev. 11:393–395. 2010.PubMed/NCBI
|
|
14
|
Gelderblom H, Hogendoorn PC, Dijkstra SD,
et al: The clinical approach towards chondrosarcoma. Oncologist.
13:320–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ozaki T, Hillmann A, Linder N, Blasius S
and Winkelmann W: Metastasis of chondrosarcoma. J Cancer Res Clin
Oncol. 122:625–628. 1996. View Article : Google Scholar
|
|
16
|
Berghuis D, Schilham MW, Santos SJ, et al:
The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth
rather than metastatic disease. Clin Sarcoma Res. 2:242012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hauer K, Calzada-Wack J, Steiger K, et al:
DKK2 mediates osteolysis, invasiveness, and metastatic spread in
Ewing sarcoma. Cancer Res. 73:967–977. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin Z, Zhao C, Han X and Han Y: Wnt5a
promotes ewing sarcoma cell migration through upregulating CXCR4
expression. BMC Cancer. 12:4802012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Teicher BA and Fricker SP: CXCL12
(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi
M and Yamamoto N: Stromal cell-derived factor-1 and CXCR4 receptor
interaction in tumor growth and metastasis of breast cancer. Biomed
Pharmacother. 60:273–276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Loberg R and Taichman RS: The
pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.
Cancer Metastasis Rev. 25:573–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun X, Cheng G, Hao M, et al:
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer
Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le Y, Zhou Y, Iribarren P and Wang J:
Chemokines and chemokine receptors: their manifold roles in
homeostasis and disease. Cell Mol Immunol. 1:95–104.
2004.PubMed/NCBI
|
|
24
|
Liberman J, Sartelet H, Flahaut M, et al:
Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant
progression of human neuroblastoma. PLoS One. 7:e436652012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar
|
|
26
|
Burger JA and Kipps TJ: CXCR4: a key
receptor in the crosstalk between tumor cells and their
microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Loetscher P, Moser B and Baggiolini M:
Chemokines and their receptors in lymphocyte traffic and HIV
infection. Adv Immunol. 74:127–180. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aiuti A, Webb IJ, Bleul C, Springer T and
Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for
human CD34+ hematopoietic progenitor cells and provides
a new mechanism to explain the mobilization of CD34+
progenitors to peripheral blood. J Exp Med. 185:111–120.
1997.PubMed/NCBI
|
|
29
|
Scotton CJ, Wilson JL, Scott K, et al:
Multiple actions of the chemokine CXCL12 on epithelial tumor cells
in human ovarian cancer. Cancer Res. 62:5930–5938. 2002.PubMed/NCBI
|
|
30
|
Sun YX, Wang J, Shelburne CE, et al:
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers
(PCa) in vivo. J Cell Biochem. 89:462–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smith MC, Luker KE, Garbow JR, et al:
CXCR4 regulates growth of both primary and metastatic breast
cancer. Cancer Res. 64:8604–8612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Orimo A, Gupta PB, Sgroi DC, et al:
Stromal fibroblasts present in invasive human breast carcinomas
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12
secretion. Cell. 121:335–348. 2005. View Article : Google Scholar
|
|
33
|
Zhou Y, Larsen PH, Hao C and Yong VW:
CXCR4 is a major chemokine receptor on glioma cells and mediates
their survival. J Biol Chem. 277:49481–49487. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Barbero S, Bonavia R, Bajetto A, et al:
Stromal cell-derived factor 1alpha stimulates human glioblastoma
cell growth through the activation of both extracellular
signal-regulated kinases 1/2 and Akt. Cancer Res. 63:1969–1974.
2003.PubMed/NCBI
|
|
35
|
Hideshima T, Chauhan D, Hayashi T, et al:
The biological sequelae of stromal cell-derived factor-1alpha in
multiple myeloma. Mol Cancer Ther. 1:539–544. 2002.PubMed/NCBI
|
|
36
|
Ponomaryov T, Peled A, Petit I, et al:
Induction of the chemokine stromal-derived factor-1 following DNA
damage improves human stem cell function. J Clin Invest.
106:1331–1339. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ceradini DJ, Kulkarni AR, Callaghan MJ, et
al: Progenitor cell trafficking is regulated by hypoxic gradients
through HIF-1 induction of SDF-1. Nat Med. 10:858–864. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Begley L, Monteleon C, Shah RB, Macdonald
JW and Macoska JA: CXCL12 overexpression and secretion by aging
fibroblasts enhance human prostate epithelial proliferation in
vitro. Aging Cell. 4:291–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Petit I, Szyper-Kravitz M, Nagler A, et
al: G-CSF induces stem cell mobilization by decreasing bone marrow
SDF-1 and up-regulating CXCR4. Nat Immunol. 3:687–694. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chinni SR, Sivalogan S, Dong Z, et al:
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in
prostate cancer cells: the role of bone microenvironment-associated
CXCL12. Prostate. 66:32–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perissinotto E, Cavalloni G, Leone F, et
al: Involvement of chemokine receptor 4/stromal cell-derived factor
1 system during osteosarcoma tumor progression. Clin Cancer Res.
11:490–497. 2005.PubMed/NCBI
|
|
42
|
Feng Y, Broder CC, Kennedy PE and Berger
EA: HIV-1 entry cofactor: functional cDNA cloning of a
seven-transmembrane, G protein-coupled receptor. Science.
272:872–877. 1996. View Article : Google Scholar
|
|
43
|
Wegner SA, Ehrenberg PK, Chang G, Dayhoff
DE, Sleeker AL and Michael NL: Genomic organization and functional
characterization of the chemokine receptor CXCR4, a major entry
co-receptor for human immunodeficiency virus type 1. J Biol Chem.
273:4754–4760. 1998. View Article : Google Scholar
|
|
44
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Schioppa T, Uranchimeg B, Saccani A, et
al: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp
Med. 198:1391–1402. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zagzag D, Krishnamachary B, Yee H, et al:
Stromal cell-derived factor-1alpha and CXCR4 expression in
hemangioblastoma and clear cell-renal cell carcinoma: von
Hippel-Lindau loss-of-function induces expression of a ligand and
its receptor. Cancer Res. 65:6178–6188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Phillips RJ, Mestas J, Gharaee-Kermani M,
et al: Epidermal growth factor and hypoxia-induced expression of
CXC chemokine receptor 4 on non-small cell lung cancer cells is
regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian
target of rapamycin signaling pathway and activation of hypoxia
inducible factor-1alpha. J Biol Chem. 280:22473–22481. 2005.
|
|
48
|
Bachelder RE, Wendt MA and Mercurio AM:
Vascular endothelial growth factor promotes breast carcinoma
invasion in an autocrine manner by regulating the chemokine
receptor CXCR4. Cancer Res. 62:7203–7206. 2002.PubMed/NCBI
|
|
49
|
Zagzag D, Lukyanov Y, Lan L, et al:
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in
glioblastoma: implications for angiogenesis and glioma cell
invasion. Lab Invest. 86:1221–1232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li YM, Pan Y, Wei Y, et al: Upregulation
of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer
Cell. 6:459–469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ao M, Franco OE, Park D, Raman D, Williams
K and Hayward SW: Cross-talk between paracrine-acting cytokine and
chemokine pathways promotes malignancy in benign human prostatic
epithelium. Cancer Res. 67:4244–4253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang L, Yeger H, Das B, Irwin MS and
Baruchel S: Tissue microenvironment modulates CXCR4 expression and
tumor metastasis in neuroblastoma. Neoplasia. 9:36–46. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang M, Wang L, Ren T, Xu L and Wen Z:
IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma
cells. Cancer Biol Ther. 14:155–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tang CH, Chuang JY, Fong YC, Maa MC, Way
TD and Hung CH: Bone-derived SDF-1 stimulates IL-6 release via
CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis
in human oral cancer cells. Carcinogenesis. 29:1483–1492. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang CY, Lee CY, Chen MY, et al: Stromal
cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma
cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell
Physiol. 221:204–212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Balabanian K, Lagane B, Infantino S, et
al: The chemokine SDF-1/CXCL12 binds to and signals through the
orphan receptor RDC1 in T lymphocytes. J Biol Chem.
280:35760–35766. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Burns JM, Summers BC, Wang Y, et al: A
novel chemokine receptor for SDF-1 and I-TAC involved in cell
survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Miao Z, Luker KE, Summers BC, et al: CXCR7
(RDC1) promotes breast and lung tumor growth in vivo and is
expressed on tumor-associated vasculature. Proc Natl Acad Sci USA.
104:15735–15740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang J, Shiozawa Y, Wang Y, et al: The
role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in
prostate cancer. J Biol Chem. 283:4283–4294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kollmar O, Rupertus K, Scheuer C, et al:
CXCR4 and CXCR7 regulate angiogenesis and CT26. WT tumor growth
independent from SDF-1. Int J Cancer. 126:1302–1315.
2010.PubMed/NCBI
|
|
61
|
Uto-Konomi A, McKibben B, Wirtz J, et al:
CXCR7 agonists inhibit the function of CXCL12 by down-regulation of
CXCR4. Biochem Biophys Res Commun. 431:772–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liekens S, Schols D and Hatse S:
CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell
mobilization. Curr Pharm Des. 16:3903–3920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Duda DG, Kozin SV, Kirkpatrick ND, Xu L,
Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway
inhibition: an emerging sensitizer for anticancer therapies? Clin
Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gustin JA, Ozes ON, Akca H, et al: Cell
type-specific expression of the IkappaB kinases determines the
significance of phosphatidylinositol 3-kinase/Akt signaling to
NF-kappa B activation. J Biol Chem. 279:1615–1620. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li Y, Chinni SR and Sarkar FH: Selective
growth regulatory and pro-apoptotic effects of DIM is mediated by
AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci.
10:236–243. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
66
|
Katiyar SK and Meeran SM: Obesity
increases the risk of UV radiation-induced oxidative stress and
activation of MAPK and NF-kappaB signaling. Free Radic Biol Med.
42:299–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Leelawat K, Leelawat S, Narong S and
Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4
induced cholangiocarcinoma cell invasion. World J Gastroenterol.
13:1561–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Burger M, Glodek A, Hartmann T, et al:
Functional expression of CXCR4 (CD184) on small-cell lung cancer
cells mediates migration, integrin activation, and adhesion to
stromal cells. Oncogene. 22:8093–8101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Lai TH, Fong YC, Fu WM, Yang RS and Tang
CH: Stromal cell-derived factor-1 increase alphavbeta3 integrin
expression and invasion in human chondrosarcoma cells. J Cell
Physiol. 218:334–342. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ryu CH, Park SA, Kim SM, et al: Migration
of human umbilical cord blood mesenchymal stem cells mediated by
stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38
signal transduction pathways. Biochem Biophys Res Commun.
398:105–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Heinrich EL, Lee W, Lu J, Lowy AM and Kim
J: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated
signaling pathways in pancreatic cancer cells. J Transl Med.
10:682012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Laverdiere C, Hoang BH, Yang R, et al:
Messenger RNA expression levels of CXCR4 correlate with metastatic
behavior and outcome in patients with osteosarcoma. Clin Cancer
Res. 11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lin F, Zheng SE, Shen Z, et al:
Relationships between levels of CXCR4 and VEGF and blood-borne
metastasis and survival in patients with osteosarcoma. Med Oncol.
28:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Baumhoer D, Smida J, Zillmer S, et al:
Strong expression of CXCL12 is associated with a favorable outcome
in osteosarcoma. Mod Pathol. 25:522–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Fan TM, Barger AM, Fredrickson RL,
Fitzsimmons D and Garrett LD: Investigating CXCR4 expression in
canine appendicular osteosarcoma. J Vet Intern Med. 22:602–608.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Oda Y, Yamamoto H, Tamiya S, et al: CXCR4
and VEGF expression in the primary site and the metastatic site of
human osteosarcoma: analysis within a group of patients, all of
whom developed lung metastasis. Mod Pathol. 19:738–745. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ma Q, Zhou Y, Ma B, et al: The clinical
value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study.
Oncol Lett. 3:797–801. 2012.PubMed/NCBI
|
|
78
|
Bai S, Wang D, Klein MJ and Siegal GP:
Characterization of CXCR4 expression in chondrosarcoma of bone.
Arch Pathol Lab Med. 135:753–758. 2011.PubMed/NCBI
|
|
79
|
Bennani-Baiti IM, Cooper A, Lawlor ER, et
al: Intercohort gene expression co-analysis reveals chemokine
receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer
Res. 16:3769–3778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kim SY, Lee CH, Midura BV, et al:
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the
development of murine pulmonary metastases. Clin Exp Metastasis.
25:201–211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
de Nigris F, Rossiello R, Schiano C, et
al: Deletion of Yin Yang 1 protein in osteosarcoma cells on cell
invasion and CXCR4/angiogenesis and metastasis. Cancer Res.
68:1797–1808. 2008.PubMed/NCBI
|
|
83
|
Miura K, Uniyal S, Leabu M, et al:
Chemokine receptor CXCR4-β1 integrin axis mediates tumorigenesis of
osteosarcoma HOS cells. Biochem Cell Biol. 83:36–48. 2005.
|
|
84
|
Hendrix CW, Collier AC, Lederman MM, et
al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a
selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir
Immune Defic Syndr. 37:1253–1262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
De Clercq E: The AMD3100 story: the path
to the discovery of a stem cell mobilizer (Mozobil). Biochem
Pharmacol. 77:1655–1664. 2009.PubMed/NCBI
|
|
86
|
Devine SM, Flomenberg N, Vesole DH, et al:
Rapid mobilization of CD34+ cells following
administration of the CXCR4 antagonist AMD3100 to patients with
multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol.
22:1095–1102. 2004.PubMed/NCBI
|
|
87
|
Cashen A, Lopez S, Gao F, et al: A phase
II study of plerixafor (AMD3100) plus G-CSF for autologous
hematopoietic progenitor cell mobilization in patients with Hodgkin
lymphoma. Biol Blood Marrow Transplant. 14:1253–1261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kim HY, Hwang JY, Kim SW, et al: The CXCR4
antagonist AMD3100 has dual effects on survival and proliferation
of myeloma cells in vitro. Cancer Res Treat. 42:225–234. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kalatskaya I, Berchiche YA, Gravel S,
Limberg BJ, Rosenbaum JS and Heveker N: AMD3100 is a CXCR7 ligand
with allosteric agonist properties. Mol Pharmacol. 75:1240–1247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lapteva N, Yang AG, Sanders DE, Strube RW
and Chen SY: CXCR4 knockdown by small interfering RNA abrogates
breast tumor growth in vivo. Cancer Gene Ther. 12:84–89. 2005.
View Article : Google Scholar : PubMed/NCBI
|
